Phase 1b combination study of Tazemetostat with Tecentriq (atezolizumab) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 15 May 2018

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tazemetostat (Primary) ; Atezolizumab
Indications Diffuse large B cell lymphoma
Focus Adverse reactions; Proof of concept
Sponsors Genentech

Most Recent Events

08 May 2018 This trial has enrolled 45 patients with DLBCL till date, according to an Epizyme media release.
09 Mar 2017 According to an Epizyme media release, company expects the optimal dose will be established this year.
03 Nov 2016 According to an Epizyme media release, status changed from planning to recruiting.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight